California researchers screened some 850 miRNAs to uncover one that inhibits growth in cancer cells with KRAS mutations, which are linked to poor survival.
MiR-371-3p diminished tolerance to targeted cancer treatment in cell lines and mice, while tolerant cells had enhanced levels of genes regulated by miR-371-3p.
Sistemic will provide its SistemRNA suite of drug development tools in order to accelerate Redx's preclinical development pipeline of more than 250 new drug candidates.
The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.
In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.